Skip to main content
SpringerLink
Log in

Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease

  • Chapter
Drugs for the Treatment of Parkinson’s Disease

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

Abstract

The development of levodopa therapy for Parkinson’s disease (PD) has spawned substantive clinical and scientific gains related to the experimental therapeutics of neurodegenerative disorders. Levodopa therapy has resulted in symptomatic benefit and increased life expectancy for the majority of PD patients. The rational development of levodopa therapy and related therapies to rectify the consequences of reduced dopaminergic neurotransmission in PD has also served as a prototype for the experimental therapeutics of other neurologic disorders associated with neurotransmitter deficits. In spite of these advances, the clinical and scientific limitations of replacement therapies have become increasingly evident. Symptomatic anti-PD benefits have proved transient, and clinical features intensify eventually in the setting of progressive neuronal degeneration. Disabling adverse effects, such as mental status disturbances, involuntary movements, and autonomic instability, further preclude or limit the use of dopaminergic therapies. The application of rational replacement therapy to other neurologic disorders has been constrained by the progressive and often multiple transmitter disturbances arising from neurode-generation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ambani LM, Van Woert WH, Murphy S (1975) Brain peroxidase and catalase in Parkinson’s disease. Arch Neurol 32: 114–118

    Article  PubMed  CAS  Google Scholar 

  • Aquilonius SM, Hartvig P (1986) Utilization of antiparkinson drugs in Sweden 1977–1984 (abstr). Ups J Med Sci [Suppl] 43: 93

    Google Scholar 

  • Backlund EO, Granberg PO, Hamberger B, Knutsson E, Martensson A, Sedvall G, Sciger A, Olson L (1985 a) Transplantation of adrenal medullary tissue to striatum in parkinsonism: first clinical trials. J Neurosurg 62: 169–173

    Google Scholar 

  • Backlund EO, Granberg PO, Hamberger B, Sedvall G, Sciger A, Olson A ( 1985 b) Transplantation of adrenal medullary tissue to striatum in parkinsonism. In: Bjorklund A, Stenevi U (eds) Neural grafting in the mammalian CNS. Elsevier, Amsterdam, pp 551–556

    Google Scholar 

  • Ballard PA, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (NY) 35: 949–956

    CAS  Google Scholar 

  • Bannon MJ, Goedert M, Williams B (1984) The possible relation of glutathione, melanin, and l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine ( MPTP) to Parkinson’s disease. Biochem Pharmacol 33: 2697–2698

    Article  PubMed  CAS  Google Scholar 

  • Barbeau A, Roy M, Langston JW (1985 a) Neurological consequence of industrial exposure to l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. Lancet 1: 747

    Google Scholar 

  • Barbeau A, Roy M, Paris S, Cloutier T, Plasse L, Poirier J (1958 b) Ecogentics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet 11: 1213–1216

    Google Scholar 

  • Barbeau A, Roy M, Cloutier T, Plasse L, Paris S (1987) Environmental and genetic factors in the etiology of Parkinson’s disease. Adv Neurol 45: 299–306

    PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19: 170–176

    PubMed  CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Trans 64: 113–127

    Article  CAS  Google Scholar 

  • Bjorklund A, Stenevi U (1979) Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 177: 555–560

    Article  PubMed  CAS  Google Scholar 

  • Calne DB (1970) Parkinsonism: physiology, pharmacology and treatment. Williams and Wilkins, Baltimore

    Google Scholar 

  • Calne DB, Langston JW, Martin WRW et al. (1985) Positron emission tomography after MPTP: observations relating to the cause of Parkinson’s disease. Nature 317: 246–248

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Eisen A, McGeer E, Spencer P (1986) Alzheimer’s disease, Parkinson’s disease, and motorneuron disease: abiotropic interactions between aging and environment? Lancet 11: 1067–1070

    Article  Google Scholar 

  • Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578

    Article  PubMed  CAS  Google Scholar 

  • Cohen G (1983) The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 89–103

    CAS  Google Scholar 

  • Cohen G (1985) Oxidative stress in the nervous system. In: Sies H (ed) Oxidative stress. Academic, London, pp 383–402

    Google Scholar 

  • Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1984) Pargyline and deprenyl prevent the neurotoxicity of MPTP in monkeys. Eur J Pharmacol 106: 209–210

    Article  PubMed  CAS  Google Scholar 

  • Cote LJ, Kremzner LT (1983) Biochemical changes in normal aging in human brain. Adv Neurol 38: 19–30

    PubMed  CAS  Google Scholar 

  • Cox DR (1972) Regression models and life tables. JR Statist Soc B 34: 187–220

    Google Scholar 

  • Cox DR, Oakes D (1983) The analysis of survial data. Chapman and Hall, New York

    Google Scholar 

  • Csanda E, Tarczy M (1983) Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 117–122

    Article  CAS  Google Scholar 

  • D’Amato RJ, Lipman ZP, Snyder SH (1986) Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231: 987–989

    Article  PubMed  Google Scholar 

  • Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1986) Lipid peroxidation as cause of nigral death in Parkinson’s disease. Lancet 11: 639–640

    Article  Google Scholar 

  • Drucker-Colin R, Madrazo I, Diaz V, Torres C (in press) Open microsurgical autograft of adrenal medulla to caudate nucleus of patients with Parkinson’s disease: report of 8 cases. In: Gash DM, Sladek JR (eds) Transplantation in the mammalian CNS: preclinical and clinical studies. Prog Brain Res 73

    Google Scholar 

  • Eisler T, Calne DB, Ebert MH, Kopin IJ, Ziegler MG, Levine R, Murphy DL (1975) Biochemical measurements during (-)-deprenyl treatment of parkinsonism. In: Sincer T, Van Korff R, Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic, New York, pp 497–505

    Google Scholar 

  • Fahn S, Bressman SB (1984) Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 11: 200–206

    PubMed  CAS  Google Scholar 

  • Fleiss JL (1981) Statistical methods for rates and proportions, 2nd edn. Wiley, New York (table 6A.3)

    Google Scholar 

  • Forno LS, Langston JW, DeLanney Le, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449–455

    Article  PubMed  CAS  Google Scholar 

  • Freed WJ, Olson L, Ko GN, Morihisa JM, Niehoff D, Stromberg I, Kuhar M Hoffer BJ, Wyatt RJ (1985) Intraventricular substantia nigra and adrenal medulla grafts: mechanisms of action and [3H] spirogeridol autoradiography. In: Bjorklund A, Stenevi U (eds) Neural grafting in the mammalian CNS. Elsevier, Amsterdam, pp 471–489

    Google Scholar 

  • Goetz CG, Shannon KM, Carroll S, Klawans HL (1986) Progression of Parkinson’s disease in patients not treated with levodopa, (abstr). Ann Neurol 20: 148

    Google Scholar 

  • Graham DG (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson’s disease. Neurotoxicology (Park Forest II ) 5: 83–96

    CAS  Google Scholar 

  • Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, Felten DL (1986) Aged mice are more sensitive to l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine treatment than young adults. Neurosci Lett 70: 326–331

    Article  PubMed  CAS  Google Scholar 

  • Heikkila RE, Manzino L, Cabbat RS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology (NY) 17: 427–442

    CAS  Google Scholar 

  • Johnson G (1976) Studies of the mechanisms of 6-hydroxydopamine cytotoxicity. Med Biol 54: 406–420

    Google Scholar 

  • Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58: 343–346

    Article  PubMed  CAS  Google Scholar 

  • Kitt CA, D’Amato RJ, Alexander CM, Schwartzman RJ, Compton AL, Joh TH, Snyder SH, Price DL (1986) Effects of chloroquine on the neurotoxicity of MPTP in monkey. Soc Neurosci Abstr 12: 209

    Google Scholar 

  • Langston JW, Ballard PA (1983) Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-l,2,5,6-tetrahydropyridine. N Engl J Med 309: 310

    PubMed  CAS  Google Scholar 

  • Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980

    Article  PubMed  CAS  Google Scholar 

  • Langston JW, Irwin I, Langston EB (1984 a) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482

    Google Scholar 

  • Langston JW, Langston EB, Irwin I (1984b) MPTP-induced parkinsonism in human and non-human primates—clinical and experimental aspects. Acta Neurol Scand 70 (Suppl 100): 49–54

    Google Scholar 

  • Madrazo I, Drucker-Colin R, Dfaz-Simental V, Torres C (1986) Open microsurgical autograft of adrenal medulla to the right caudate nucleus in human intractable Parkinson’s disease. Soc Neurosci Abstr 12: 563

    Google Scholar 

  • Mann DMA, Yates PO (1947) Lipoprotein pigments: their relationship to aging in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97: 489–498

    Article  Google Scholar 

  • Martilla RJ (1983) Diagnosis and epidemiology of Parkinson’s disease. Acta Neurol Scand [Suppl] 95: 9–17

    Article  Google Scholar 

  • McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal function. Arch Neurol 34: 33–35

    Article  PubMed  CAS  Google Scholar 

  • McNeill TH, Koek LL, Haycock JW, Gash DM (1986) Glutathione reduction mimics MPTP neurotoxicity and age-correlated changes in dopamine neurons in substantia nigra of the C57BL/6NNia mouse. Soc Neurosci Abstr 12: 1470

    Google Scholar 

  • Morihisa JM, Nakamura RK, Freed WJ, Mishkin M, Wyatt RJ (1984) Adrenal medulla grafts survive and exhibit catecholamine-specific fluorescence in the primate brain. Exp Neurol 84: 643–653

    Article  PubMed  CAS  Google Scholar 

  • Perlow MJ, Freed WJ, Hoffer BJ, Sciger A, Olson L, Wyatt RJ (1979) Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204: 643–647

    Article  PubMed  CAS  Google Scholar 

  • Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269–274

    Article  PubMed  CAS  Google Scholar 

  • Quinn N, Critchley P, Parkes D, Marsden CD (1986) When should levodopa be started? Lancet 11: 985–986

    Article  Google Scholar 

  • Rajput AH, Offord KP, Beard CM, Kurland LT (1984) Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 16: 278–282

    Article  PubMed  CAS  Google Scholar 

  • Redmond DE, Sladek JR, Roth RH, Collier TJ, Elsworth JD, Deutch AY, Haber S (1986) Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1: 1125–1127

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Jellinger K, Seemann D (1984) Monoamine oxidase and parkinsonism. In: Tipton KF, Dostert P, Benedetti MS (eds) Monoamine oxidase and disease. Academic, New York, pp 403–415

    Google Scholar 

  • Robinson DS (1975) Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc 34: 103–107

    PubMed  CAS  Google Scholar 

  • Scheinberg IH, Sternlieb I (1984) Wilson’s disease. Saunders, Philadelphia

    Google Scholar 

  • Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. Livingston, Edinburgh, pp 152–157

    Google Scholar 

  • Schwarcz R, Shoulson I (1987) Excitotoxins and Huntington’s disease. In: Coyle JT (ed) Experimental models of dementing disorders: a synaptic neurochemical approach. Liss, New York, pp 39–68

    Google Scholar 

  • Shoulson I (1983) Huntington’s disease: anti-neurotoxic therapeutic strategies. In: Fuxe K, Roberts P, Schwarcz R (eds) Excitotoxins, (Wenner-Gren symposium series). MacMillan, New York, pp 343–353

    Google Scholar 

  • Shoulson I, The Parkinson Study Group (1987) Correlates of clinical decline in early Parkinson’s disease (abstr). Neurology 37 (Suppl 1): 278

    Google Scholar 

  • Shou-Shu J, Wa-Cheng Z, Minh-Chen D, Jia-Bang S (in press) The clinical study of adrenal medullary tissue transplantation to striatum in parkinsonism. In: Gash DM, Sladek JR (eds) Transplantation in the mammalian CNS: preclinical and clinical studies. Prog Brain Res 73

    Google Scholar 

  • Slivka A, Cohen G (1985) Hydroxyl radical attack on dopamine. J Biol Chem 260: 15 466–15

    Google Scholar 

  • Snyder SH, D’Amato RJ (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson’s disease. Neurology 36: 250–258

    PubMed  CAS  Google Scholar 

  • Stampfer MJ, Buring JE, Wilett W, Rosner B, Eberlein K, Hennekens CH (1985) The 2x2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians. Stat Med 4: 111–116

    Article  PubMed  CAS  Google Scholar 

  • Tanner CM (1986) Influence of environmental factors on the onset of Parkinson’s disease (abstr). Neurology 36 (Suppl 1): 215

    Google Scholar 

  • Tetrud J, Langston WJ (1986) Early parkinsonism in humans due to MPTP exposure. Neurology 36 (Suppl 1): 308

    Google Scholar 

  • Van Woert MH, Ambani LM (1974) Biochemistry of neuromelanin. Adv Neurol 5: 215–222

    PubMed  Google Scholar 

  • Vyas I, Heikkila RE, Nicklas WJ (1986) Studies on the neurotoxicity of MPTP. Inhibition of NAD-linked substrate oxidation by its metabolite, MPP+. J Neurochem 46: 1501–1507

    Article  PubMed  CAS  Google Scholar 

  • Wooten GF (1984) Parkinsonism. In: Pearlman AL, Collins RC (eds) Pathophysiology, 3rd ed. Oxford University Press, New York, pp 365–377

    Google Scholar 

  • World Almanac (1986) Disability insurance benefits and wage earning. Newspaper Enterprise, New York, pp 68–72, 114

    Google Scholar 

  • Wright JM, Wall RA, Perry TL, Paty DW (1983) Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. N Engl J Med 310: 325

    Google Scholar 

Download references

Authors
  1. I. Shoulson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shoulson, I. (1989). Experimental Therapeutics Directed at the Pathogenesis of Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation